March 6th 2024
In the third part of this video series, Susan Cantrell, CEO of AMCP, discusses the impact of drug prices on patient adherence with Managed Healthcare Executive.
Anthem strikes deal with Gilead Sciences making Harvoni the primary treatment for hep C
January 13th 2015Health insurer Anthem has reached a deal that makes Gilead Sciences’ Harvoni the primary treatment for patients with hepatitis C, following close on the heels of hep C drug announcements by CVS Health and Express Scripts.
Read More
AARP study finds sharp rise in price of brand name prescription drugs
November 21st 2014Retail prices for brand name prescription drugs widely used by older Americans shot up by an average of nearly 13% in 2013, more than eight times faster than the 1.5% general inflation rate, according to a new AARP Public Policy Institute report.
Read More
Weighing the benefits of anti-obesity drugs
November 11th 2014espite the fact that approximately 2.74 million patients used anti-obesity drugs in 2011, according to information services company IMS Health, the majority of health plans are following the lead of the Centers for Medicare and Medicaid Services and not covering them.
Read More